PHILADELPHIA, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic...
Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients...
PHILADELPHIA, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic...
On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads